Location History:
- Hurth, DE (2018)
- Cologne, DE (2023)
Company Filing History:
2 out of 24 
1 out of 1,291 
Years Active: 2018-2023
Title: Bernd Neumaier: Innovator in Imaging Probes
Introduction
Bernd Neumaier is a notable inventor based in Hurth, Germany, recognized for his contributions to the field of imaging probes. With a total of two patents, his work focuses on enhancing the visualization of prostate-specific membrane antigen (PSMA) expressing tissues, which is crucial for the diagnosis of prostate cancer.
Latest Patents
Neumaier's latest patents include innovative compounds such as 2-alkoxy-6-[18F]fluoronicotinoyl substituted lys-c(O)-glu derivatives. These compounds have been identified as efficient imaging probes for PSMA expressing tissues, outperforming other known PSMA specific ligands. The 6-[F]fluoro-2-alkoxy and 6-[F]fluoro-4-alkoxy substituted analogs demonstrated significant differences in cellular uptake in PSMA expressing prostate tumor cells. The 2-alkoxy derivative exhibited higher cellular uptake values compared to [F]DCFPyL, while the 4-alkoxy derivative showed lower uptake. In vivo PET studies revealed that the 2-alkoxy-substituted probes provided excellent visualization of PSMA positive ganglia, making them valuable for diagnosing small prostate cancer lesions. Additionally, Neumaier developed efficient methods for producing 18F-labeled active esters, which are essential for creating PSMA-specific PET tracers.
Career Highlights
Throughout his career, Neumaier has worked with prestigious institutions such as the Max Planck Society for the Advancement of Science and the University of Cologne. His research has significantly advanced the field of medical imaging, particularly in the context of prostate cancer diagnosis.
Collaborations
Neumaier has collaborated with notable colleagues, including Boris Zlatopolskiy and Raphael Richarz, contributing to the development of innovative imaging techniques.
Conclusion
Bernd Neumaier's work in the field of imaging probes has made a significant impact on the diagnosis of prostate cancer. His innovative patents and collaborations highlight his dedication to advancing medical imaging technology.